NANO-X IMAGING LTD NNOX

LOS ANGELES, CA - September 11, 2026 (NEWMEDIAWIRE) - Nanox (NASDAQ: NNOX) announced a distribution agreement with Costa Rica-based medical equipment distributor SOLME RC, S.A. to market and support the Nanox.ARC, a multi-source digital tomosynthesis...

Agreement with SOLME RC, SA Marks the third Latin American market this year PETACH TIKVA, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (NASDAQ: NNOX) ("Nanox"), a leader in innovative medical imaging technology, today announced a distribution agreement with SOLME RC, S.A. (“SOLME”), a Costa Rica-based medical equipment distributor serving public and private healthcare institutions nationwide, to market and support the Nanox.ARC in Costa Rica. Nanox.ARC is a multi-source digital

Nano X Imaging Ltd (NNOX) reports strong top-line growth driven by teleradiology services, while navigating a $40.7 million impairment and cash conservation efforts.

Nanox (NASDAQ:NNOX) reported a 37% increase in second-quarter 2026 revenue to $4. 2 million, but its GAAP net loss widened to $55.

Management to host conference call and webcast on Wednesday, September 9, 2026 at 8:30 AM ETPETACH TIKVA, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2026, and provided a business update. Recent Business Highlights: Expanded Nanox’s presence in the U.S. through additional distribution partner agreement.Advanced capital equipm

LOS ANGELES, CA - September 8, 2026 (NEWMEDIAWIRE) - Nanox (NASDAQ: NNOX), through its U.S.-based subsidiary Nanox Impact Inc., entered into a distribution agreement with Associated X-Ray Imaging Corp. to support deployment of the Nanox.ARC across Ne...

Expands Nanox’s growing U.S. distribution network with a leading New England-based medical imaging provider PETACH TIKVA, Israel — September 4 2026 — Nano-X Imaging Ltd. (“Nanox”, or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has entered into a distribution agreement with Associated X-Ray Imaging Corp., a New England-based provider of medical imaging equipment and services, specializing in X-

LOS ANGELES, CA - August 27, 2026 (NEWMEDIAWIRE) - Nanox (NASDAQ: NNOX), an innovative medical imaging technology company, announced it will report financial results for the quarter ended June 30, 2026, before market open on Sept. 9, 2026. CEO and Ac...

The company combines proprietary imaging hardware, FDA-cleared AI applications, cloud software, radiology services and healthcare IT within an end-to-end platform spanning scan, analysis and interpretation. Nanox is expanding its commercial reach th...

PETACH TIKVA, Israel, Aug. 25, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2026, before market open on Monday, September, 9, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Guy Nathanzon, Chief Financial Officer, will host a conference call to review these results and provide a business update beg

Initial three-year term includes minimum annual license commitments PETACH TIKVA, ISRAEL, August 18 2026 -- Nanox Imaging Ltd. (“Nanox”, or the “Company” NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced its subsidiary, Nanox AI Ltd. (“Nanox AI”) entered into a sales reseller agreement with Vertec Scientific Ltd. (“Vertec”) for the commercialization of Nanox.AI bone solution (HealthOST) in the United Kingdom. The agreement grants Vertec an exclusive license to mar

PETACH TIKVA, Israel, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd. (Nasdaq: NNOX), (“Nano-X” or the “Company”) an innovative medical imaging technology company, today announced that it has entered into a securities purchase agreement with a single long-term institutional investor for the purchase and sale of 8,000,000 Ordinary Shares (or prefunded warrants in lieu of any portion thereof) (the “Ordinary Shares”) and warrants to purchase up to 8,000,000 Ordinary Shares at a combined purch

New SCCT abstracts from Brigham and Women’s Hospital highlight the performance and clinical utility of Nanox.AI’s FDA-cleared cardiac AI solution, showing high agreement with expert assessment and its potential role in supporting guideline-directed preventive care. From incidental finding to clinical action: the AI INFORM randomized trial highlights how AI-detected coronary calcium may help clinicians identify opportunities for preventive lipid-lowering therapy. Nanox.AI Sponsors SCCT Scientific

Nano X Imaging Ltd (NNOX) reports increased revenues and strategic partnerships, but faces cash flow concerns and revised revenue targets.